FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER

被引：0
|
作者：
Konecny, Gottfried [1 ]
Hendrickson, Andrea Wahner [2 ]
Winterhoff, Boris [3 ]
Chander, Cinthiya [1 ]
Bilic, Sanela [4 ]
Davenport, Simon [5 ]
Chung, Adrine [6 ]
Miller, Lei-Lani [6 ]
Press, Michael [5 ]
Letrent, Stephen [7 ]
Slamon, Dennis [8 ]
机构：
[1] UCLA, Obstet & Gynecol, Los Angeles, CA USA
[2] Mayo Clin, 200 First St Sw, Rochester, MN USA
[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA
[4] Vanadro, Pharmacol, Urbandale, IA USA
[5] Univ Southern Calif, Dept Pathol, Los Angeles, CA USA
[6] Translat Res Oncol US, Clin Operat, Los Angeles, CA USA
[7] TORL Biotherapeut, Clin Dev, Culver City, CA USA
[8] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期
关键词：
D O I：
10.1136/ijgc-2023-IGCS.102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR062
引用
收藏
页码：A67 / A67
页数：1
相关论文
共 50 条
  • [1] First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
    Konecny, G. E.
    Hendrickson, A. E. Wahner
    Winterhoff, B.
    Machado, A.
    Chander, C.
    Davenport, S.
    Bilic, S.
    Miller, L. L.
    Chung, A.
    Press, M. F.
    Letrent, S.
    Slamon, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S517 - S517
  • [2] Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.
    Konecny, Gottfried E.
    Hendrickson, Andrea Elisabeth Wahner
    Winterhoff, Boris
    Chander, Cinthiya
    Bilic, Sanela
    Davenport, Simon
    Chung, Adrine
    Miller, Lei-Lani
    Press, Michael F.
    Letrent, Stephen P.
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Phase I, two-part, mutlicenter, first-in-human (FIH) study of TORL-1-23, a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patients with advanced solid tumors
    Konecny, Gottfried
    Hendrickson, Andrea Wahner
    Winterhoff, Boris
    Kung, Adrine
    Miller, Lei-Lani
    Press, Michael
    Qazi, Ibrahim
    Scholler, Nathalie
    Dokainish, Hatem
    Letrent, Stephen
    Slamon, Dennis
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A56 - A56
  • [4] Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors
    Konecny, G. E.
    Hendrickson, A. E. Wahner
    Winterhoff, B.
    Adjei, A. A.
    Kung, A.
    Miller, L-L.
    Press, M. F.
    Qazi, I.
    Scholler, N.
    Dokainish, H.
    Letrent, S.
    Slamon, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S551 - S551
  • [5] Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6
    Patel, M. R.
    Hamilton, E. P.
    Piha-Paul, S. A.
    Henry, J.
    Banerji, U.
    Al Hallak, M. N.
    Okada, H.
    Qian, M.
    Zhang, X.
    Said, N.
    Chatikhine, V.
    Fontana, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S488 - S489
  • [6] A FIRST-IN-HUMAN TRIAL OF AN INTEGRIN BETA-6 TARGETED ANTIBODY-DRUG CONJUGATE (ADC), SGNB6A, IN PATIENTS WITH ADVANCED SOLID TUMORS: INTERIM RESULTS OF A PHASE 1 STUDY (SGNB6A-001)
    Hollebecque, Antoine
    Lopez, Juanita
    Piha-Paul, Sarina
    Dowlati, Afshin
    Patnaik, Amita
    Galvao, Vladimir
    Buckorny, Bruno
    Sehgal, Kartik
    Kingsley, Edwin
    Sanborn, Rachel
    Peters, Solange
    Sun, Yan
    Patilea-Vrana, Gabriela
    Nazarenko, Natalya
    Calvo, Emiliano
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A763 - A763
  • [7] A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors
    Wang, Jie
    Wu, Lin
    Song, Zhengbo
    Li, Xingya
    Liu, Caigang
    Liu, Tianshu
    Wu, Yiwen
    Zhang, Ze
    Wang, Shuni
    CANCER RESEARCH, 2023, 83 (08)
  • [8] A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
    Spira, Alexander I.
    Lee, Elizabeth Katherine
    O'Cearbhaill, Roisin Eilish
    LoRusso, Patricia
    Falchook, Gerald Steven
    Patel, Manish R.
    Richardson, Debra L.
    Lu, Nicole Covino Wei
    Marreddy, Priya
    Farrington, Daphne L.
    Wheler, Jennifer J.
    Slosberg, Eric Daniel
    Subbiah, Vivek
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers
    Ko, Andrew H.
    Coveler, Andrew L.
    Schlechter, Benjamin L.
    Bekaii-Saab, Tanios S.
    Wolpin, Brian M.
    Clark, Jeffrey William
    Cheng, Yi-Lin
    Cheng, Ting-Ying
    Langecker, Peter J.
    Lin, Shih-Yao
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] A first-in-human trial of the integrin beta-6-targeted antibody-drug conjugate, SGN-B6A, in patients with advanced solid tumors
    Calvo, E.
    Hollebecque, A.
    Dowlati, A.
    Piha-Paul, S. A.
    Galvao, V.
    Lopez, J.
    Sehgal, K.
    Bockorny, B.
    Braiteh, F.
    Peters, S.
    Sanborn, R. E.
    Zhou, P.
    Nazarenko, N.
    Patnaik, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S613 - S613
12345